Mentored Investigator Grant
(Formerly Ann and Sol Schreiber Mentored Investigator Award)
The Mentored Investigator Grant provides funding for trainees (post-doctoral fellows or clinical fellows) who are working under the supervision of a mentor who is a recognized leader in the field of ovarian cancer research. Applicants must have an MD or a PhD degree. The grant provides a total of $75,000 to be used over one or two years, and will encourage the recipient’s research career in the field of ovarian cancer.
2023 Grant Recipients
-
Chae Young Han, PhD,
MD Anderson Cancer Center
Detection of CA125-Negative Persistent and Recurrent Ovarian Cancer
-
Apoorva Uboveja, PhD,
University of Pittsburgh
A Metabolic-Epigenetic Switch Affects DNA Repair Pathway Choice
-
Sonam Mittal, PhD,
Medical College of Wisconsin
Exosome Loaded eIF4A1 Dependent Translational Reprogramming in Macrophages
-
Antonio Delgado-Gonzalez, PhD,
Stanford University
Mapping the Spatial Proteomic Landscape of Ovarian Tumors
-
Joshua Eggold, PhD,
University of Pennsylvania
Functional Characterization of Distinct Ovarian Cancer Macrophage Subsets
-
Bisiayo Fashemi, PhD,
Washington University in St. Louis
Organoids to Evaluate an Epigenetic Drug Regimen for HR Proficient Ovarian
-
Chen Wang, PhD,
MD Anderson Cancer Center
Epigenetically Targeting Ovarian Cancer Associated Mesenchymal Stem Cells
-
Andres Valdivia, PhD,
Northwestern University
Complement Activation at the Interface Between Cancer Cells and Adipocytes
-
Duaa Al-Rawi, MD, PhD,
Memorial Sloan Kettering Cancer Center
Examining the Early Events in Fallopian Tube Transformation
2022 Grant Recipients
-
Thales Nepomuceno, PhD,
Moffitt Cancer Center and Research Institute
Tackling PARPi sensitivity in HRP and HRD cells
-
Zelei Yang, PhD,
Dana Farber Cancer Institute
Re-engaging the Anti-tumor Immune Response Against Ovarian Cancer
-
Imade Williams, PhD,
Indiana University
Targeting MYC-HSF1 co-Amplification in High Grade Serous Ovarian Cancer
-
Erin Wesley, PhD,
University of Minnesota Twin Cities
Impact of Cytomegalovirus and Inflammation on NK Cells in Ovarian Cancer
-
Amrita Salvi, PhD,
The University of Illinois at Chicago
Investigating the mechanism of action of PHY34 in HGSOC
-
Pamela Rojas de Santiago, PhD,
University of Pennsylvania
Investigating the Therapeutic Potential of CRABP2 in HGSOC
-
Veethika Pandey, PhD,
University of Pennsylvania
Overcoming T Cell Exhaustion in Ovarian Cancer Tumor Microenvironment
-
Benjamin Johnson, PhD,
Van Andel Research Institute
Ovarian Cancer Stem-like Cell Differentiation Trajectories in Single Cells
-
Patrick Innamarato, PhD,
Moffitt Cancer Center and Research Institute
Determination of the Immunogenic Antigen Repertoire in Ovarian Cancer
-
Melica Brodeur, MD,
Memorial Sloan Kettering Cancer Center
Exploiting SMARCA4 Alterations for New Therapeutics in Ovarian Cancers
-
Gamze Bildik Elcik, PhD,
MD Anderson Cancer Center
DIRAS3 Inhibits KRAS and Sensitizes LGSOC Cells to Anti-autophagic Therapy
2021 Grant Recipients
-
Anup Singh, PhD,
La Jolla Institute for Immunology
Studying the Role of BRCA1 in Regulating Heterochromatin Structure and Function in Ovarian Cancer
-
Melanie Weigert, PhD,
University of Chicago
Genome-Wide Profiling of 5-hydroxymethylcytosine on Cell-Free DNA
-
Anne M. van Harten, PhD,
Thomas Jefferson University
Targeted MDM2 Degradation as a Novel Treatment for Ovarian Cancer
-
Bojana Stefanovska, PhD,
University of Minnesota Twin Cities
APOBEC3B and DNA Repair as Synthetic Lethal Combinations in CCOC
-
Sammy Ferri-Borgogno, PhD,
MD Anderson Cancer Center
Spatially-Resolved Cellular and Transcriptome Analyses of Ovarian Cancer
-
Sridevi Challa, PhD,
UT Southwestern Medical Center
Role of Ribosomal Protein Mono(ADP-ribosyl)ation in Protein Quality Control
-
Benoît Bragantini, PhD,
Mayo Clinic
Probing Homologous Recombination DNA Repair Factors in Chromatin by cryo-EM
-
Ronja Anugwom, PhD,
MD Anderson Cancer Center
Determine Resistance Mechanisms to ATR Inhibition in Ovarian Cancers
-
Wei Zhou, PhD,
The Wistar Institute
Targeting the mevalonate pathway in ARID1A-mutated ovarian cancer
-
Xueyang Yu, PhD,
Massachusetts Institute of Technology
Macrophage Control of the Microenvironment Drives HGSOC Progression
2020 Grant Recipients
-
David Chapel, MD,
Brigham and Women’s Hospital
The Migratory Precursor and Serous Carcinogenesis
-
Yilun Deng, PhD,
University of Texas Health Science Center at San Antonio
CD122-Selective IL-2 Complexes as Novel Ovarian Cancer Therapy
-
Elizabeth Lee, MD,
Dana Farber Cancer Institute
Phase II Trial of Gemcitabine+ATR Inhibitor: Translational Studies
-
Jianhuang Lin, PhD,
The Wistar Institute
Targeting ER Stress Pathway in CARM1-Expressing Ovarian Cancer
-
Duygu Ozmadenci, PhD,
University of California - San Diego
Sensitizing Ovarian Cancer to Immunotherapies
-
Elizabeth Raupach, PhD,
The Translational Genomics Research Institute
Oncogenic Consequences of Altered SWI/SNF-RNA Interactions in SCCOHT
-
Camilla Salvagno, PhD,
Weill Medical College of Cornell University
Dissecting How ER Stress Responses Shape Ovarian Cancer Immuno-Environments
-
Janice Santiago, PhD,
MD Anderson Cancer Center
Crizotinib Improves the Therapeutic Efficacy of Olaparib in Ovarian Cancer
-
Ignacio Vázquez-García, PhD,
Memorial Sloan Kettering Cancer Center
Co-Evolution and Dynamics of Malignant and Immune Cells in Ovarian Cancer
-
Morozov Yaroslav, PhD,
University of Pennsylvania
The BRCA1-A as a Determinant of Chemotherapy Response in ATM Mutated Cells
2019 Grant Recipients
-
Kristin G. Anderson, PhD,
Fred Hutchinson Cancer Research Center
Engineering Adoptive T Cell Therapy for Efficacy in Ovarian Cancer
-
Alexander Cole, PhD,
Magee-Womens Research Institute
Investigating Regulators of Quiescence in Epithelial Ovarian Cancer
-
Sarah Gitto, PhD,
University of Pennsylvania
Modeling Autologous TIL Therapy in Novel PARP Resistant PDX Model for Ovarian Cancer
-
Guy Katz, MD, PhD,
MD Anderson Cancer Center
Therapeutic miRNA Targeting for Ovarian Cancer
-
Isaac Klein, MD, PhD,
Dana Farber Cancer Institute
Transcriptional Regulatory Landscape of High Grade Serous Ovarian Cancer
-
John Krais, PhD,
Fox Chase Cancer Center
Examining the Role of RNF168 in BRCA1 Mutant Ovarian Cancer
-
Marilyne Labrie, PhD,
Oregon Health and Science University
Synergistic Lethality of PARP and P13K Pathway Inhibitors in Ovarian Cancer
-
Jing Li, MD, PhD,
University of Michigan
ARID1A Drives Ovarian Cancer Immunotherapy
-
Shariska Petersen, MD,
University of Kansas Medical Center Research Institute
Cyclin E and BRD4 as Markers for a New PARPi Drug Combination
-
Alba Rodriguez-Garcia, PhD,
University of Pennsylvania
Targeting MISIIR with CAR T Cells for the Treatment of Ovarian Cancer
-
Elaine Stur, PhD,
MD Anderson Cancer Center
Re-activating Anti-tumor Immunity Targeting PSEN1 in CAFS in Ovarian Cancer
-
Shuai Wu, PhD,
The Wistar Institute
Synthetic Lethality for ARID1A Mutation in Ovarian Cancer
-
Haineng Xu, PhD,
University of Pennsylvania
A Novel Targeted Therapy for Cyclin E Over Expressing Ovarian Cancers
-
Zvi Yaari, PhD,
Memorial Sloan Kettering Cancer Center
Implantable Nanosensor for Early-Stage Detection of Ovarian Cancer
2018 Grant Recipients
-
Damayanti Chakraborty, PhD,
Massachusetts General Hospital
Understanding Epigenetic Regulation of Copy Number Gains in Ovarian Cancer
-
Daniele Chaves-Moreira, PhD,
University of Pennsylvania
Isolation and Characterization of the PAX8 Transcriptional Complex
-
Chin-Chi Chen, PhD,
Johns Hopkins University
Determining the Role of ARID1A in 53BP1-mediated DNA Damage Repair
-
Shih-Hsun Chen, PhD,
Beckman Research Institute of the City of Hope
Targeting de-poly (ADP-ribosyl)ation for Ovarian Cancer Therapy
-
Matthew Dean, PhD,
University of Illinois - Chicago
The Ovarian Microenvironment in Metastasis of Fallopian Tube Derived Cancer
-
Marcela Haro, PhD,
Cedars-Sinai Medical Center
Cancer Associated Fibroblasts Hinder the B Cell Anti-Tumor Response
-
Ye Hu, MD, PhD,
Cedars-Sinai Medical Center
Reciprocal Roles of CAFs and CD4+ T Cells in Cancer Progression
-
Justyna Kanska, PhD,
Cedars-Sinai Medical Center
Identifying Synthetic Lethal Targets to Mutant p53 in Development of HGSOC
-
Goldie Lui, PhD,
Fred Hutchinson Cancer Research Center
Identifying Novel Targeted Therapies for MYC-driven Ovarian Cancer
-
Sarah Stuckelberger, MD,
University of Pennsylvania
Development of A Novel Syngeneic Model System for Ovarian Cancer Research
-
Yinu Wang, PhD,
Northwestern University
Characterization of Chromatin Nanoarchitecture of Ovarian Cancer Stem Cells
-
Shuang Zhang, PhD,
New York University School of Medicine
Modeling Human HGSOC Using Fallopian Tube Organoid Cultures
2017 Grant Recipients
-
Nabanita Chatterjee, PhD,
MD Anderson Cancer Center
Ovarian Cancer Disrupts Circadian Cortisol Rhythms
-
Marion Curtis, PhD,
University of Chicago
Mediators of Chemosensitivity and Immunotherapy Targets
-
Anniina Farkkila, MD, PhD,
Dana Farber Cancer Institute
Overcoming PARP Inhibitor Resistance in Ovarian Cancer
-
Jagmohan Hooda, PhD,
University of Pennsylvania
Loss of H2Bub1 Rewires Glutamine Metabolism During Progression of HGSOC
-
Gilbert Huang, PhD,
MD Anderson Cancer Center
Targeting Dormant Ovarian Cancer Cells with Peptide Inhibitors of Autophagy
-
Dongyu Jia, PhD,
Cedars-Sinai Medical Center
COL11A Is A Highly Specific Therapeutic Target in Cancer-Activated Stroma
-
Venkatesh Krishnan, PhD,
Stanford University
Omental Macrophages: Drivers of Ovarian Cancer Metastasis
-
Xianzhi Lin, PhD,
Cedars-Sinai Medical Center
Systematic Discovery of LncRNA Interactome in Epithelial Ovarian Cancer
-
Beatrice Rondinelli, PhD,
Dana Farber Cancer Institute
EZH2 Determines PARPi Resistance and Fork Stabilization in Ovarian Tumors
-
Priyanka Verma, PhD,
University of Pennsylvania
BRCA-Independent DNA Repair Pathways in Ovarian Cancer
2016 Grant Recipients
-
Jessica Chacon, PhD,
University of Pennsylvania
Investigating the Role of Immunosuppressive Molecules in Ovarian Cancer
-
Song Yi Ko, PhD,
MD Anderson Cancer Center
A “Trojan Horse” Mechanism That Mediates Resistance to Anti-VEGF Therapy
-
Jill Madden, PhD,
Inc., University of Kansas Medical Center Research Institute
The Effect of FoxM1 Inhibition on Ovarian Cancer Immunity and Sensitivity
-
Abir Mukherjee, PhD,
University of Chicago
Microenvironment Mediated Stabilization of Hif-1 Alpha in Ovarian Cancer
-
Debarshi Roy, PhD,
Mayo Clinic
Crosstalk Between Glycolytic Pathway Inhibition and Increased Autophagy
-
Qian Tan, MD, PhD,
Stanford University
Activation of Macrophages by Inhibiting CD47 Signaling in Ovarian Cancers
-
Ryan Williams, PhD,
Memorial Sloan Kettering Cancer Center
An Ovarian Cancer Biosensor for Rapid, Non-invasive Disease Detection
-
Nur Yucer, PhD,
Cedars-Sinai Medical Center
Modeling Mullarian HGSC Using BRCA1 Patient Derived iPSCs
-
Fan Zhao, PhD,
Stanford University
Ovarian Cancer Antigen Discovery by Single t-cell Analysis and pHLA Library
-
Hengrui Zhu, PhD,
The Wistar Institute
Epigenetic Targeting of Cancer Stem-like Cells (CSCs) in Ovarian Cancer
2015 Grant Recipients
-
Juan Cubillos-Ruiz, PhD,
Weill Medical College of Cornell University
ER Stress Sensor XBP1 as a Key Regulator of Ovarian Cancer Immunity
-
Justyna Filant, PhD,
MD Anderson Cancer Center
Novel Extra Cellular RNA-based Combinatorial RNA Inhibition Therapy
-
Xiaowen Hu, PhD,
University of Pennsylvania
Long Non-coding RNAs in Epithelia Ovarian Cancer
-
Petar Jelinic, PhD,
Memorial Sloan Kettering Cancer Center
EMSY Suppresses HDR in a BRCA2-interaction-independent Manner
-
Zeina Kais, PhD,
Dana Farber Cancer Institute
Synthetic Lethality Between CCNE1 Amplification and USP1 Inhibition
-
Bob McGray, PhD,
Roswell Park Cancer Institute
Combination Oncolytic Virotherapy/ACT for Ovarian Cancer Treatment
-
Alfredo Perales-Puchalt, MD,
The Wistar Institute
Targeting FSH Receptor with Chimeric Antigen Receptor in Ovarian Cancer
-
Nicole Spardy, PhD,
Dana Farber Cancer Institute
Identification of New Genetic Dependencies in HR-deficient Ovarian Cancers
-
Wei Wei, PhD,
Massachusetts General Hospital
Genomic Analysis to Predict Recurrence in Early Stage Ovarian Cancer
-
Oladapo Yeku, MD, PhD,
Memorial Sloan Kettering Cancer Center
A Phase I Trial Using Chimeric Antigen Receptors in Ovarian Cancer Patients
2014 Grant Recipients
-
Nima Aghaeepour, PhD,
Stanford University
Computationally-guided Characterization of Therapy-resistant Ovarian Tumors
-
Raphael Ceccaldi, PharmD, PhD,
Dana Farber Cancer Institute
A Bioinformatic Screen Identifies POLQ Overexpression in Ovarian Cancers
-
Ilana Chefetz, PhD,
University of Michigan
A Role for ALDH in the Regulation of Necroptosis in Ovarian Cancer Area of research: Therapeutic Targeting
-
Ellen Cheon, PhD,
Cedars-Sinai Medical Center
Collagen-Remodeling Genes Provide a Niche for Ovarian Cancer
-
Laura Dillon, PhD,
University of Virginia
Differential MicroDNA Generation in Ovarian Cancer
-
Mo Li, PhD,
University of Michigan
Mechanism of PARP Inhibitor in Ovarian Cancer Therapy Cancer
-
Kyung Hee Noh, PhD,
MD Anderson Cancer Center
Targeting Adaptive Changes to anti-VEGF Therapy in Ovarian Cancer
-
Shailja Pathania, PhD,
Dana Farber Cancer Institute
Novel Therapeutic Targets for High-Grade Serous Ovarian Carcinoma
-
Megan Rice, ScD,
Brigham and Women’s Hospital
Dietary Fat, Cholesterol, and Ovarian Cancer Risk
-
Yang Yang, PhD,
Yale University
P53 Aggregation: a New Target to Combat Ovarian Cancer Platinum-Resistance
-
Chi Lam Au Yeung, PhD,
MD Anderson Cancer Center
Adipose Tissue Derived Exosomal miRNAs in Ovarian Cancer Progression
-
Yuyu Yuyu, PhD,
Johns Hopkins University School of Medicine
Targeting Spleen Tyrosine Kinase in Chemoresistant Ovarian Cancer
2013 Grant Recipients
-
Pradeep Chaluvally-Raghavan, PhD,
MD Anderson Cancer Center
Role of microRNAs in the 3q26 Amplicon in Ovarian Cancer Pathophysiology and Therapy
-
Ronald Chandler, PhD,
University of North Carolina - Chapel Hill
A Genetically Relevant Mutant Mouse Model of Epithelial Ovarian Cancer
-
Diana Hargreaves, PhD,
Stanford University
Targeting Ovarian Cancer via Cooperative Oncogene Interactions
-
Christine Lawson, PhD,
University of California - San Diego
Testing the FAK and Talin Signaling Linkage in Ovarian Tumor Cell Metastasis
-
Teng Ma, MD, PhD,
University of Michigan - Ann Arbor
The Analysis of NEDD8-activating Enzyme Inhibitor MLN4924 on Ovarian Cancer
-
David Pepin, PhD,
Massachusetts General Hospital
Mechanisms and Markers to Target a Stem Enriched Population of Primary Ovarian Cancer Ascites with the Müllerian Inhibiting Substance
-
Yin Wang, PhD,
Mayo Clinic Jacksonville
Protein Kinase C iota is a Novel Therapeutic Target for Ovarian Cancer Treatment
2012 Grant Recipients
-
Bin Guan, PhD,
Johns Hopkins University School of Medicine
Functional Characterization of the Tumor Suppressor ARID1A in Ovarian Cancer
-
Kate Lawrenson, PhD,
University of Southern California
Modeling Stem Cell Origins of Epithelial Ovarian Carcinomas
-
Hanqing Liu, PhD,
Fox Chase Cancer Center
Targeting Signaling Networks via RNAi to Improve Therapy for Ovarian Cancer
-
Ngai Na Co, PhD,
MD Anderson Cancer Center
The Role of Stromal microRNA 21 in Omental Ovarian Cancer Progression
-
See-Hyoung Park, PhD,
Stanford University
Targeting Ovarian Cancer with Combination of Olaparib and Bepridil
-
Melinda Yates, PhD,
MD Anderson Cancer Center
Unraveling the Initiation of Ovarian Cancer: The BRCA1-Heterozygous Mouse as a Model System
2011 Grant Recipients
-
Anirban Mitra, PhD,
University of Chicago
How Do Cells Near Ovarian Cancer Cells Play a Role in the Disease?
-
Gregory Motz, PhD,
University of Pennsylvania
Stimulating Immune Cells to Fight Ovarian Cancer
-
Ruth Perets, MD, PhD,
Dana Farber Cancer Institute
Trying to Identify the Cell Responsible for Ovarian Cancer
-
Sharmistha Sarkar, PhD,
MD Anderson Cancer Center
Finding a Marker to Detect Early Stage Ovarian Cancer
-
Sherry Wu, PhD,
MD Anderson Cancer Center
Novel Approach to Destroy the Blood Supply that Feeds Ovarian Cancer Tumors
-
Tsz-Lun Yeung, PhD,
MD Anderson Cancer Center
Understanding How Ovarian Cancer Spreads
2008 Grant Recipients
-
Weiwei Shan, PhD,
MD Anderson Cancer Center
Cellular Microenvironment Role in Ovarian Cancer Development
-
Takayo Ota, MD, PhD,
Mayo Clinic Rochester
Characterizing the Genetic Alterations of Aggressive Ovarian Cancer
-
Xiaoping He, MD, PhD,
Mayo Clinic Rochester
Understanding the Molecular Pathways to Chemotherapy Resistance in Ovarian Cancer
-
Thuy-Vy Do, PhD,
Fox Chase Cancer Center
Understanding How Ovarian Cancer Spreads
-
Lejla Delic, MD,
Cedars-Sinai Medical Center
A New Class of Drugs with Potential Against Ovarian Cancer: PARP-inhibitors
2007 Grant Recipients
-
Hong Zhang, PhD,
Fox Chase Cancer Center
Novel Animal Model to Test Drugs Against Ovarian Cancer
-
Melissa Merritt, PhD,
Brigham and Women’s Hospital
How Might Different Tissues in the Ovary Act on Each Other to Induce Cancer
-
Mitchell Cheung, PhD,
Fox Chase Cancer Center
Testing New Therapeutic Agents to Treat Ovarian Cancer
-
Kuang-Hung Cheng, PhD,
Brigham and Women’s Hospital
Animal Model to Study Ovarian Cancer Stem Cells
2006 Grant Recipients
-
Ramandeep Rattan, PhD,
Mayo Clinic
Gene May Be an Early Marker for Ovarian Cancer
-
Andres Matoso, MD,
Cornell University
An Animal Model to Study Major Genetic Alterations in Ovarian Cancer
-
Aliza Leiser, MD,
Yale University
Clinical Implications of the TLR-4MYD88 Pathway in EOC
-
Audrey Gagnon, PhD,
Brigham and Women’s Hospital
New Analytical Tool for Ovarian Cancer Detection
-
Adam Clauss, PhD,
Dana Farber Cancer Institute
Does Ovarian Cancer Originate in the Fallopian Tube?
-
Maria Barbolina, PhD,
University of Illinois - Chicago
Epigenetic Regulation of Metastasis-Associated Gene Expression in EOC
-
Tsukasa Baba,
Duke University
Using Public Resources to Find New Drugs to Treat Resistant Ovarian Cancer
2005 Grant Recipients
-
Deyin Xing, MD, PhD,
Massachusetts General Hospital
Models to Study Hereditary Ovarian Cancer
-
Jason Wilken, PhD,
Yale University
Making an Antibody Treatment for Breast Cancer Work for Ovarian Cancer
-
Ritu Salani, MD,
Johns Hopkins University School of Medicine
DNA Fragments Might be a Way to Screen for Ovarian Cancer
-
Joseph Kwong, PhD,
Brigham and Women’s Hospital
Could Inflammation of Ovarian Cells be the Cause of Ovarian Cancer?
-
Amy BonDurant, MD,
Duke University
Chemical Changes on DNA May Be a Way to Screen for Ovarian Cancer and its Recurrence
-
Donna Badgewell, PhD,
MD Anderson Cancer Center
Developing a Screening Test for Ovarian Cancer
2004 Grant Recipients
-
Xiaoyan Ni, PhD,
Brigham and Women’s Hospital
Biomarkers for Ovarian Cancer
-
Brian Barnett, MD,
Tulane University Health Sciences Center
Depleting Regulatory T Cells to Treat Ovarian Cancer
2003 Grant Recipients
-
Monique Spillman, MD, PhD,
Duke University Medical Center
Role of MAP2K4 Suppressing Metastasis of Serous Ovarian Cancers
-
Naomi Hunder, MD,
Fred Hutchinson Cancer Research Center
Evaluation of Mesothelin as a Taret Antigen in Ovarian Cancer
-
Kuan-Chun Huang, PhD,
Brigham and Women’s Hospital
A Possible New Marker for Drug Resistance of Ovarian Cancer
-
Jeremy Chien, PhD,
Mayo Clinic
How Cell Shape Changes Lead to Metastasis in Ovarian Cancer